Isolation Bio

Executive Summary

Isolation Bio is a San Francisco-based biotechnology company specializing in high-throughput, automated microbial isolation and cultivation. Its flagship Prospector® Discovery Platform enables rapid discovery of live microbes from complex environmental and clinical samples, such as soil and feces, for microbiome research and product development. Founded in 2021, the company serves diverse sectors including human health, animal health, agriculture, and environmental science. By streamlining the isolation process, Isolation Bio aims to accelerate the development of microbiome-based therapeutics, probiotics, and agricultural solutions. The platform addresses a critical bottleneck in microbiome research: the majority of environmental microbes remain unculturable using traditional methods. Isolation Bio’s technology has potential to unlock novel microbial strains for applications ranging from drug discovery to crop enhancement. As a private entity with no disclosed funding, the company operates in a competitive landscape of microbiome tool companies but differentiates through its automation and throughput capabilities. Its success will hinge on commercial adoption, partnerships, and securing growth capital.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of next-generation Prospector platform70% success
• Q1 2027Strategic partnership with a pharmaceutical or agricultural company60% success
• Q2 2027Series A funding round to scale operations65% success